“Peripheral Artery Disease – 5EU China Drug Forecast and Market Analysis to 2024”. The Report covers current Market Trends, Analysis, Forecast, Review, Share, Size, Growth, Effect.
In the 2014 base year, the global PAD market was worth approximately $543.4m, including both branded and generic drugs. By 2024, GlobalData expects that the global PAD market will experience significant expansion, with a Compound Annual Growth Rate (CAGR) of approximately 4.15%, equating to around $816.3m. The dramatic increase in the value of the overall global PAD therapeutics market will be partly attributable to the launch of several PAD drugs currently in late-stage pipeline development, which GlobalData believes have extraordinary potential. These include the novel antithrombotic pharmacological agents, Merck & Co.s Zontivity (vorapaxar), AstraZenecas Brilinta (ticagrelor), and Bayer and Janssens (a subsidiary of Johnson & Johnson) Xarelto (rivaroxaban), which have the capacity to reform the antiplatelet and anticoagulatory PAD treatment landscape.
To Free Sample Report With TOC @ http://www.researchmoz.us/enquiry.php?type=S&repid=816335
Total 5EU sales for the PAD therapeutics market in 2014 was approximately $198.8m. By 2024, sales of drugs that are used to relieve the symptoms of PAD will decline quite dramatically. This group of medicines will only contribute approximately 5% to total 5EU PAD sales by the end of the forecast period.
*This is an on-demand report and will be delivered within 24 hrs. (excluding weekends) of the purchase.
– Overview of PAD including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
– Detailed information on the key drugs in 5EU including product PADcription, safety and efficacy profiles as well as a SWOT analysis.
– Sales forecast for the top drugs in 5EU from 2014-2024.
– Analysis of the impact of key events as well the drivers and restraints affecting 5EU PAD market.
To Enquire Regarding This Report @ http://www.researchmoz.us/enquiry.php?type=E&repid=816335
Reasons to buy
– Understand and capitalize by identifying products that are most likely to ensure a robust return
– Stay ahead of the competition by understanding the changing competitive landscape for PAD.
– Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
– Make more informed business decisions from insightful and in-depth analysis of drug performance
– Obtain sales forecast for drugs from 2014-2024 in 5EU.
For More Information Kindly Contact:
ResearchMoz Global Pvt. Ltd.
90 State Street,
Albany, NY 12207,
Blog – http://bit.ly/2b1Ayn6
866-997-4948 (Us-Canada Toll Free),
Email to: email@example.com,